title: In AF or VTE, warfarin dosing by genotype improved time in therapeutic range but not clinical outcomes.
authors.forename: Andrew
authors.initials: A
authors.lastname: Dunn
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives*; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004151:Dipeptides / Q000627:therapeutic use*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male
chemical_list: D004151:Dipeptides; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D000218:Adamantane